BioInvent receives notice of allowance in China for BI-1206 patent
This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
- This patent allowance is a strategic milestone in BioInvent's exclusive licensing agreement with CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China.
- In 2020, CASI gained the rights for the development and commercialization of BI-1206 in mainland China, Taiwan, Hong Kong, and Macau.
- Other patents in the same patent family have already been granted by the European Patent Office and in several other countries, including the US and Japan.
- The company also has related patent applications pending in some countries.